.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Boston Scientific recently announced a significant TAVR system investment in MiRus LLC, a move that signals their aggressive return to the heart valve market. This $1.5 billion deal secures a 34% equity stake in the privately held startup. Furthermore, the agreement provides a clear path for a potential full acquisition of the heart-valve business. Consequently, this partnership highlights the growing importance of advanced transcatheter technologies in modern cardiology.
The primary driver behind this TAVR system investment is the development of the SIEGEL valve. Currently, the creators of this experimental device intend it for patients suffering from severe aortic stenosis. Notably, the SIEGEL valve aims to offer a balloon-expandable solution, a sector Boston Scientific exited previously. However, rising demand for minimally invasive cardiac procedures prompted this strategic pivot. In addition, the deal includes potential acquisition rights for mitral and tricuspid valve assets.
Boston Scientific previously exited the balloon-expandable market due to complex regulatory hurdles. Now, the company aims to meet those challenges through the innovative technology developed by MiRus. Specifically, the SIEGEL valve represents a next-generation approach to treating valvular narrowing. If MiRus achieves specific clinical milestones, Boston Scientific may pay an additional $3 billion for full ownership. This underscores their commitment to leading the cardiovascular device space globally. Moreover, the investment will likely influence the competitive landscape for TAVR systems in the coming years.
Q1: What is the purpose of the SIEGEL valve mentioned in the deal?
The SIEGEL valve is an experimental balloon-expandable device designed to treat patients with severe aortic stenosis. It is not currently approved for commercial sale in any country.
Q2: Why did Boston Scientific decide to re-enter the TAVR market?
Boston Scientific is re-entering this market to capture growth in the balloon-expandable segment, despite their previous exit due to high clinical and regulatory requirements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Boston Scientific invests $1.5 billion in MiRus LLC to re-enter the TAVR market, focusing on the experimental SIEGEL valve for treating aortic stenosis....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
